Hepatitis C virus infection among injecting drug users in Scotland: a review of prevalence and incidence data and the methods used to generate them

K. M. ROY1*, S. J. HUTCHINSON1,2, S. WADD1, A. TAYLOR3, S. O. CAMERON4, S. BURNS5, P. MOLYNEAUX6, P. G. MCINTYRE7 AND D. J. GOLDBERG1

1 Health Protection Scotland, Clifton House, Clifton Place, Glasgow, Scotland
2 Public Health and Health Policy Section, University of Glasgow, Scotland
3 School of Social Sciences, University of Paisley, Scotland
4 Specialist Virology Centre, Gartnavel General Hospital, Glasgow, Scotland
5 Specialist Virology Centre, Royal Infirmary of Edinburgh, Edinburgh, Scotland
6 Department of Medical Microbiology, Aberdeen Royal Infirmary, Aberdeen, Scotland
7 Department of Medical Microbiology, Ninewells Medical School, Dundee, Scotland

( Accepted 24 May 2006; first published online 8 August 2006)

SUMMARY

It is estimated that of 50 000 persons in Scotland (1% of the county’s population), infected with the hepatitis C virus (HCV), around 90% injected drugs. This paper reviews data on the prevalence and incidence of HCV, and the methods used to generate such information, among injecting drug users (IDUs), in Scotland. The prevalence estimate for HCV among IDUs in Scotland as a whole (44% in 2000), is comparable with those observed in many European countries. Incidence rates ranged from 11.9 to 28.4/100 person-years. The data have shaped policy to prevent infection among IDUs and have informed predictions of the number of HCV-infected IDUs who will likely progress to, and require treatment and care for, severe HCV-related liver disease. Although harm reduction interventions, in particular needle and syringe exchanges and methadone maintenance therapy, reduced the transmission of HCV among IDUs during the early to mid-1990s, incidence in many parts of the country remains high. The prevention of HCV among IDUs continues to be one of Scotland’s major public health challenges.

INTRODUCTION

Since the mid-1990s, Health Protection Scotland (HPS; formerly the Scottish Centre for Infection and Environmental Health) has coordinated the country’s hepatitis C virus (HCV) infection surveillance programme. The data generated indicate that, as in other resource-rich countries, the population in Scotland most at risk of infection are those who have injected drugs. Scotland, probably, has one of the highest injecting drug use, and HCV among injecting drug users (IDUs), prevalences in Europe; an estimated 89 900 current and former IDUs, of whom 45 500 were HCV infected resided in Scotland during 2005 [1].

Data on the prevalence and incidence of HCV among IDUs are crucial in informing those responsible for developing and evaluating strategies to prevent transmission of infection and services for those infected. In this paper, the authors review the results of, and different methods employed in, surveys undertaken to estimate HCV prevalence and incidence among this population in Scotland. As a country,
with a population of 5,000,000, Scotland is culturally and economically typical of many resource-rich countries in the world.

METHODS

Several information sources were accessed to collect data for this review. Studies published between 1990 and 2005 (inclusive) were identified through a computerized search (Medline and EMBASE) using relevant key words and MeSH headings. A search for publications using a list of the names of Scottish researchers known by the authors to be working in the relevant field of work was undertaken. As HPS is often involved directly, or indirectly, in HCV surveillance and research conducted throughout the country, a hand search of the library of papers and unpublished documents to which staff had contributed was performed.

National surveillance data and reports (published and unpublished) on the prevalence and incidence of HCV seropositivity among IDUs in Scotland were reviewed; studies based on self-reported HCV status were excluded. For each study, the following information was recorded: characteristics of the population tested [NHS Board area in which IDUs either (i) resided, (ii) attended health service clinics or (iii) were in prison], the numbers of specimens and the proportion found to be HCV antibody positive, the method used to obtain specimens, the specimen type, the year the specimen was collected and the setting in which the specimen was taken.

RESULTS

Since 1991 when antibody tests to detect HCV became available, 23 scientific articles concerning the epidemiology of HCV in Scotland have been published in peer-review journals; of these, 14 reported studies of HCV prevalence and/or incidence among IDUs. Eight additional relevant sources of information, not commercially published or generally available, were also identified.

Prevalence of diagnosed HCV infection

National surveillance of HCV antibody-positive diagnoses

A database of all persons, known to have been infected with HCV in Scotland, was established by HPS, in association with Scotland’s principal HCV testing laboratories, in 1996 [2]. The database holds the following non-identifying data on all persons in Scotland who have had a positive anti-HCV result: forename initial, soundex code of surname, date of birth, gender, date of earliest positive specimen, source of specimen, area of residence and risk information.

By the end of June 2005, 19,422 persons had been diagnosed with HCV infection [3] of which, approximately 88%, 1 in 341 of Scotland’s population, were alive [4]. Of these, 11,777 (61%) were known to have injected drugs; no risk information was available for 6,417 cases. Geographical variations exist with the highest rate of IDU-related diagnosed infection per 100,000 in the Greater Glasgow NHS Board area (535/100,000) and the lowest in the Western Isles NHS Board area (4/100,000) (Fig. 1). The Greater Glasgow, Lothian, Tayside and Grampian NHS Board areas account for three quarters of all diagnosed IDUs.

Prevalence of diagnosed and undiagnosed HCV infection among Scottish IDUs (Table 1)

The prevalence of HCV among IDUs throughout Scotland has been derived from several retrospective and prospective surveys. Two distinct designs were employed – unlinked anonymous testing of residual sera taken from IDUs undergoing routine clinical tests and voluntary anonymous testing of saliva donated by IDUs participating in surveys.

Unlinked anonymous HCV testing surveys

Unlinked anonymous testing has been used, routinely, as an epidemiological tool in the United Kingdom since 1990. Residues of samples taken from persons belonging to certain populations for routine clinical tests are further tested for HIV, or other infections such as HCV, unless objections to such testing are raised by patients. Patient identifiers are irreversibly unlinked from their corresponding specimens so that a test result cannot be linked to an individual. Selected non-identifying information (gender, age group, source laboratory/geographical area) is retained so that it is impossible to determine the identity of any individual through deductive means. The detail surrounding the method and its ethical basis is recorded elsewhere [5, 6].

In 1997, an unlinked anonymous HCV testing survey was implemented to monitor trends in the prevalence of HCV among IDUs in four NHS Board areas.
areas, incorporating the major urban centres (Glasgow, Dundee, Aberdeen and Edinburgh) and covering 50% of the Scottish population; testing was performed, retrospectively, on residual sera from serology specimens voluntarily submitted by IDUs for attributable HIV testing during selected years since 1989 [7, 8]. In 1999–2000, the geographical coverage of the survey was expanded to include IDUs having an attributable HIV test in 12 of the 15 NHS Board areas.

Additional surveys, employing this method, have involved the HCV testing of (i) residual syphilis serology specimens from IDUs attending genitourinary medicine clinics in Glasgow, Edinburgh, Dundee and Aberdeen [9], and (ii) residual rubella serology specimens from IDUs attending antenatal clinics in Dundee [10].

The earliest serological evidence of HCV among IDUs in Scotland was derived from specimens, originally taken between 1973 and 1980, to confirm acute clinical hepatitis B infection (HBsAg+, IgM+) among IDUs in Glasgow; retrospective testing, undertaken in 1993, indicated that 59 of the 73 (81%) were anti-HCV positive (S. Cameron, personal communication). Since then, a total of 11,151 sera have been tested anonymously for HCV; 6,432 (57.6%) were antibody positive.

Of 2,141 IDUs in Scotland who underwent attributable HIV antibody testing during 1999–2000, 946 (44%) were HCV antibody positive. The highest HCV prevalence (62%) was detected among Greater Glasgow injectors; this was followed by a rate of 53% among those from Tayside and prevalences ranging from 23% to 41% among injectors in other NHS Board areas. HCV prevalence data for Borders and Island NHS Board areas were unavailable because so few injectors had presented there for HIV testing [11]. Serial data from Glasgow, Lothian, Tayside and Grampian NHS Board areas showed that the prevalence of HCV declined in the early to mid-1990s,
Table 1. Prevalence of HCV infection among different injecting drug user (IDU) populations in Scotland

<table>
<thead>
<tr>
<th>NHS Board area</th>
<th>Method</th>
<th>Year of study</th>
<th>Total</th>
<th>Aged &lt;25 years</th>
</tr>
</thead>
<tbody>
<tr>
<td>Argyll &amp; Clyde</td>
<td>UAT of serum specimens for attributable HIV testing at multiple sites</td>
<td>1999</td>
<td>59</td>
<td>18</td>
</tr>
<tr>
<td></td>
<td>UAT of serum specimens which tested anti-HBs positive</td>
<td>1997–1999</td>
<td>59</td>
<td>24</td>
</tr>
<tr>
<td>Greater Glasgow</td>
<td>UAT of serum specimens for attributable HIV testing at multiple sites</td>
<td>1990</td>
<td>295</td>
<td>264</td>
</tr>
<tr>
<td></td>
<td>UAT of serum specimens which tested HBsAg positive</td>
<td>1995</td>
<td>370</td>
<td>285</td>
</tr>
<tr>
<td></td>
<td>UAT of serum specimens taken for syphilis serology</td>
<td>1996</td>
<td>312</td>
<td>249</td>
</tr>
<tr>
<td></td>
<td>UAT of serum specimens collected in prison</td>
<td>1997</td>
<td>463</td>
<td>317</td>
</tr>
<tr>
<td>Lanarkshire</td>
<td>UAT of serum specimens for attributable HIV testing at multiple sites</td>
<td>1999</td>
<td>116</td>
<td>47</td>
</tr>
<tr>
<td></td>
<td>VAT of saliva specimens collected in prison</td>
<td>1996</td>
<td>85</td>
<td>27</td>
</tr>
<tr>
<td>Grampian</td>
<td>UAT of serum specimens for attributable HIV testing at multiple sites</td>
<td>1996</td>
<td>223</td>
<td>84</td>
</tr>
<tr>
<td></td>
<td>VAT of saliva specimens collected in prison</td>
<td>1997</td>
<td>57</td>
<td>19</td>
</tr>
</tbody>
</table>

436 K. M. Roy and others

https://doi.org/10.1017/S0950268806007035

Downloaded from https://www.cambridge.org/core. IP address: 54.70.40.11, on 05 Feb 2020 at 03:29:55, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms
<table>
<thead>
<tr>
<th>Area</th>
<th>Description</th>
<th>Year</th>
<th>Total</th>
<th>HIV</th>
<th>CI (%)</th>
<th>Total</th>
<th>HIV</th>
<th>CI (%)</th>
<th>Total</th>
<th>HIV</th>
<th>CI (%)</th>
<th>Total</th>
<th>HIV</th>
<th>CI (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tayside</td>
<td>UAT of serum specimens for attributable HIV testing at multiple sites</td>
<td>1993</td>
<td>134</td>
<td>94</td>
<td>70 (62–78)</td>
<td>47</td>
<td>27</td>
<td>57 (42–71)</td>
<td>[35]</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>1996</td>
<td>395</td>
<td>251</td>
<td>64 (59–68)</td>
<td>113</td>
<td>47</td>
<td>42 (33–51)</td>
<td>[35]</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>1997</td>
<td>162</td>
<td>106</td>
<td>65 (58–73)</td>
<td>33</td>
<td>15</td>
<td>45 (29–63)</td>
<td>[35]</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>1999</td>
<td>160</td>
<td>84</td>
<td>53 (44–60)</td>
<td>51</td>
<td>18</td>
<td>35 (23–50)</td>
<td>[35]</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>UAT of serum specimens taken for either a named or anonymous HIV test</td>
<td>1997</td>
<td>17</td>
<td>7</td>
<td>41 (16–67)</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>[35]</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lothian</td>
<td>UAT of serum specimens which tested HIV antibody negative</td>
<td>1980s</td>
<td>33</td>
<td>25</td>
<td>76 (57–88)</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>[36]</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>UAT of serum specimen taken for HbsAB testing</td>
<td>1983–1984</td>
<td>126</td>
<td>110</td>
<td>87 (82–93)</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>[37]</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>UAT of serum specimens for attributable HIV testing at multiple sites</td>
<td>1989–1990</td>
<td>1001</td>
<td>756</td>
<td>76 (73–78)</td>
<td>416</td>
<td>289</td>
<td>69 (65–74)</td>
<td>[27]</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>1995</td>
<td>306</td>
<td>177</td>
<td>58 (52–63)</td>
<td>106</td>
<td>33</td>
<td>31 (23–41)</td>
<td>[27]</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>1996</td>
<td>307</td>
<td>134</td>
<td>44 (38–49)</td>
<td>114</td>
<td>19</td>
<td>17 (11–25)</td>
<td>[27]</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>1997</td>
<td>327</td>
<td>131</td>
<td>40 (35–46)</td>
<td>112</td>
<td>15</td>
<td>13 (8–21)</td>
<td>[27]</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>1999</td>
<td>394</td>
<td>142</td>
<td>36 (31–41)</td>
<td>128</td>
<td>22</td>
<td>17 (11–25)</td>
<td>[27]</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>UAT of serum specimens taken for syphilis serology</td>
<td>1997</td>
<td>27</td>
<td>14</td>
<td>52 (32–71)</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>[8]</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>VNT of serum specimens; search of general practice records</td>
<td>2000</td>
<td>108</td>
<td>73</td>
<td>68 (59–76)</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>[38]</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Elsewhere</td>
<td>UAT of serum specimens taken for either a named or anonymous HIV test</td>
<td>1999</td>
<td>363</td>
<td>111</td>
<td>31 (26–36)</td>
<td>148</td>
<td>26</td>
<td>18 (12–25)</td>
<td>[10]</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>VAT of saliva specimens collected in prison</td>
<td>1995</td>
<td>100</td>
<td>56</td>
<td>56 (46–66)</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>[12]</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

UAT, Unlinked anonymous testing of residual sera from specimens taken for routine clinical purposes (these samples were sourced from laboratories); VAT, voluntary anonymous testing of saliva specimens taken from IDUs specifically for study purposes; VNT, voluntary named testing; CI, confidence interval.

HCV antibody in saliva is a marker of hepatitis C carriage; estimates of hepatitis C carriers have been converted to estimates of HCV antibody-positive cases.

A multiplier of 100/85 has been applied to studies throughout with the exception of the Greater Glasgow Community-wide survey undertaken in 2000–2001 where a multiplier of 100/96 was employed.

* IDUs who had commenced injecting since 1990 (for those recruited in 1999) and 1996 (for those recruited in 2001–2002).
during the period when harm reduction initiatives were introduced and developed, but remained steady in the late 1990s (Fig. 2) [12]; the decline was particularly evident among those aged <25 years. By examining serial HCV prevalences among young IDUs, the majority of whom commenced injecting drugs within the previous 5 years, potential changes in HCV incidence among this population can be gauged.

Voluntary anonymous HCV testing surveys

Cross-sectional surveys of IDUs have been conducted in Scotland since 1990. IDUs were recruited from treatment-agency, needle-exchange and street-site settings using a multi-site, community-wide sampling strategy, to ensure that as representative a sample as possible was achieved. Subject to consent, these respondents were interviewed using a structured questionnaire which included questions on IDU demography, injecting frequency, injecting equipment sharing, access to needle/syringe exchange and methadone maintenance therapy, and imprisonment; further questions have been included on attributable HCV testing (since 1996) and experience and knowledge of, and attitudes to, HCV infection (since 2001). Respondents were also asked to supply a saliva sample for the anonymous testing of HIV and/or hepatitis virus antibodies. The most recent survey, undertaken during 2001–2002 in Glasgow, also included a qualitative component that aimed to understand the reasons why IDUs continued to share injecting equipment in the era of harm reduction.

Voluntary anonymous HCV testing surveys of prisoners, incarcerated in several Scottish prisons between 1994 and 1996, have also been undertaken. Following consent, prisoners’ saliva samples were tested anonymously for HIV and HCV; the test result was linked to a self-completed questionnaire about risk behaviour that included questions on injector status, including whether they had injected while in prison. Questions on other blood exposure, such as having been tattooed, were added to the questionnaires in the later surveys [13].

For the above studies, salivary HCV antibody was initially detected using a modified Monolisa anti-HCV assay (Sanofi Pasteur, Marne-la-Coquette, France); the test had an 85% sensitivity [14]. Since 2001, a modified Murex anti-HCV 4.0 ELISA (Abbot Diagnostics, Maidenhead, UK) assay with a 96% sensitivity has been used. Throughout this paper, a multiplier (100/85 or 100/96) has been applied to convert estimates of HCV antibody in saliva to estimates of HCV antibody in blood.

Among Glasgow injectors recruited to community-wide surveys, there was a significant decline in the unadjusted prevalence of HCV antibody from 67%...
in 1990 to 56% in 1996 ($P = 0.02$). Data from the 1999 survey (of IDUs who had commenced injecting since 1990), suggested that prevalence remained steady throughout the late 1990s. The most recent studies, undertaken since 2000, reported adjusted HCV anti-body prevalences of 57%, 27% and 54% in Greater Glasgow (among IDUs who had commenced injecting since 1996) Lanarkshire and Highland respectively. The studies undertaken in the prison setting indicated that HCV prevalence was high among prisoners per se, ranging from 17% to 34% (data not shown in Table 1), and increased to 37–66% among prisoners reporting ever having injected drugs; prevalence was slightly higher among injector inmates who reported injecting in prison compared to those who had not [13].

### Incidence of HCV among Scottish IDUs (Table 2)

Few estimates of HCV incidence among IDUs in Scotland exist (Table 2). Two published studies used a cohort approach. The first, a retrospective study, involved the unlinked anonymous HCV testing of residual serum specimens from IDUs having two or more voluntary attributable HIV tests during the period 1993–1998; on the basis of 11 seroconversions observed, an incidence of 28.2/100 person-years was reported [15]. The second, a prospective study, involved the voluntary anonymous HCV testing of saliva samples collected from prison inmates on two occasions, 6 months apart; on the basis of four seroconversions among inmates who declared ever having injected drugs, an incidence of 11.9/100 person-years of incarceration was estimated [16]. Further unpublished work undertaken by HPS has estimated incidence rates indirectly by using a combination of HCV prevalence and date of injecting debut data from injectors who had commenced injecting drugs (HCV prevalence among non-IDUs in Scotland, invariably, is <1%) [17] and that cases had acquired infection

<table>
<thead>
<tr>
<th>Region</th>
<th>Method</th>
<th>Population</th>
<th>Year(s) of study</th>
<th>No. of IDUs followed</th>
<th>No. of seroconversions</th>
<th>Exposure time (p-yr)</th>
<th>Incidence per 100 p-yr† (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Greater Glasgow</td>
<td>UAT of serum specimens tested for HIV</td>
<td>IDUs with two or more named HIV tests</td>
<td>1993–1998</td>
<td>31</td>
<td>11</td>
<td>38.8</td>
<td>28.4 (15.7–51.2)</td>
</tr>
<tr>
<td>Lanarkshire</td>
<td>Prison recruitment, VAT of saliva specimen* on two occasions</td>
<td>IDU prisoners, incarcerated for at least 6 months before first specimen</td>
<td>1999–2000</td>
<td>69</td>
<td>4</td>
<td>33.5</td>
<td>11.9 (4.5–31.8)</td>
</tr>
<tr>
<td>Greater Glasgow</td>
<td>Community wide recruitment, VAT of saliva specimen*</td>
<td>Current IDUs‡</td>
<td>1990–1993</td>
<td>550</td>
<td>356</td>
<td>1264.8</td>
<td>28.1 (25.3–31.2)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>1999</td>
<td>283</td>
<td>130</td>
<td>523.2</td>
<td>24.8 (20.9–29.5)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>2001–2002</td>
<td>385</td>
<td>228</td>
<td>785.9</td>
<td>29.0 (25.5–33.0)</td>
</tr>
</tbody>
</table>

UAT, Unlinked anonymous testing; VAT, Voluntary anonymous testing; p-yr, person-years; CI, confidence interval.

* HCV antibody in saliva is a marker of hepatitis C carriage; estimates of hepatitis C carriers have been converted to estimates of HCV antibody-positive cases. A multiplier of 100/85 has been applied to studies throughout with the exception of the Greater Glasgow Community-wide survey undertaken in 2000/2001 where a multiplier of 100/96 was employed.

† Incidence calculated using person-years method, where date of seroconversion was taken as the midpoint of the follow-up period, with the exception of the study marked (§) where the date of seroconversion was taken as the end of the follow-up period.

midway through their exposure period. Such studies indicate that HCV incidence among injectors in Glasgow declined in the mid-1990s from 28/100 person-years of injecting in 1990–1993 to 21/100 person-years of injecting in 1994–1996, but increased to 25/100 in 1999 and 29/100 in 2001–2002; this trend is consistent with those observed for HCV prevalences generated through unlinked anonymous testing, as above.

**DISCUSSION**

The methods (including recruitment approach, geographical coverage and periodicity) employed to monitor HCV prevalence and incidence among IDUs in Scotland have been varied; while such differences should be considered when interpreting the data, they provide a relatively clear understanding of the extent and spread of HCV among IDUs throughout the country. A statistical modelling exercise demonstrated that, among IDUs in Glasgow, the estimated HCV incidence was consistent with the estimated HCV prevalence [18].

The population of diagnosed HCV cases is self-selected and as HCV infection, generally, is asymptomatic for many years, the number of diagnoses in Scotland represents only a proportion of the total HCV antibody-positive IDU population. Of the database’s 18 703 records, 11 212 were known to have injected drugs; it is probable, however, that a large proportion of the 6243 cases, for which no risk information was recorded, had injected drugs since 73% (4579/6243) were aged 15–44, the range within which 95% of the 11 252 IDUs belonged. If we assume that these 4579 had injected drugs and an estimated 12% of the HCV-diagnosed IDU population had died, the resulting estimated number of living diagnosed HCV antibody-positive injectors (~13 900) constitutes less than a third of the estimated 45 500 infected persons in Scotland during 2005, who had ever injected drugs [1].

The approach involving the serial voluntary anonymous testing of IDUs, recruited using a multisite, community-wide sampling strategy, is considered the optimal one for gauging changes in HCV prevalence among this population; the opportunity to obtain behavioural data which can be linked to HCV test results is an added benefit. Unfortunately, such surveys are expensive, a fact which makes it impossible for them to be performed in many centres. The unlinked anonymous surveys of injectors having an attributable non-HCV (usually HIV) related blood test, however, is a relatively inexpensive and pragmatic way of providing estimates of HCV prevalence among this group nationally. Although such IDUs are not necessarily representative of the total IDU population, real changes in its HCV prevalence can be detected through the use of this approach if it is used consistently over time. Information derived from IDUs aged <25 years, the majority of whom will have started injecting within the previous 5 years, provide compelling evidence of the incidence of infection.

The prevalence estimate for Scotland as a whole (44% in 2000, ranging from 23% to 62% depending on geographical location) is comparable with those observed in many European countries (the EU range is 30–90% [19]) and is similar to that in Australia [20]. In contrast to the prevalence of HCV, that of HIV among injectors in Scotland has remained below 1% since 1998 [21].

In parts of Scotland, particularly Glasgow, the incidence of HCV among current IDU populations decreased in the early to mid-1990s but remains high despite extensive needle/syringe exchange and methadone maintenance provision. HCV continues to spread because of its high prevalence, its high percutaneous infectivity (relative to that for HIV) [22] and because a high proportion of IDUs continue to share injecting equipment; around a third of new injectors, registered with Scotland’s drug misuse database in 2004–2005, had shared needles and syringes within the previous month [23]. Our understanding of the reasons why IDUs continue to share needles, syringes, spoons, filters and water is limited but there is some evidence to indicate that many do not perceive HIV and HCV as major threats because current IDUs infected with the former are so few and those infected with the latter rarely manifest any severe HCV-related morbidity (S. Wadd, personal communication). Further, suboptimal access to sterile injecting equipment promotes ‘sharing’ activity [24]; a survey of needle-exchange services in Scotland in 1997 found that the level of needle and syringes distributed was insufficient to provide a sterile needle and syringe per injecting episode for all injectors [25]. This issue was addressed in 2002, when the Lord Advocate (the principal Law Officer of the Crown in Scotland), relaxed the restriction on the numbers of needles and syringes that could be given to an IDU on any single visit to an exchange (a maximum of 15 has been increased to 60). The impact of this and
other initiatives such as the transfer of needle and syringe exchanges from dedicated health service sites to pharmacy-based ones and increased access to methadone maintenance therapy will be evaluated by continuously monitoring the prevalence of HCV among, particularly young, IDUs. It remains to be seen if the Scottish Executive Health Department target of a 20% reduction of HCV prevalence among IDUs between 2000 and 2005 has been met [26].

The data generated by the surveillance programme have been referenced in reports to support HCV public health policy statements at local [27], Scotland [28], United Kingdom [29, 30] and European Union [31] levels. In addition, the above data have been incorporated into statistical models designed to determine the number of HCV-infected IDUs who are likely to progress to severe HCV-related liver disease and thus require treatment and care in the future [1]; accordingly, the data will inform the local and central planning of health services regarding HCV disease.

ACKNOWLEDGEMENTS

We acknowledge the contribution of survey participants and are also grateful to the many people (virologists, clinicians, clerical workers and public health physicians) who have made important contributions to Scotland’s HCV surveillance programme.

DECLARATION OF INTEREST

None.

REFERENCES


